Vincent Guillaumot’s Post

Cube Biotech and IBA Lifesciences two pioneers joining forces, unlocking potential to drive further innovation in #biotechnology and ultimately improving patients' outcome. #ARCHIMED #ImpactingHealthcare #CubeBiotech #IBALifesciences #Lifesciences #biotech

📢 PRESS RELEASE 📢 #ARCHIMED finalizes a transformational deal for Cube Biotech with the acquisition of IBA Lifesciences. This strategic acquisition highlights Cube Biotech’s vision to accelerate innovation, streamline services, and expand global outreach, following several key partnerships already concluded in the past 12 months. To read the full Press Release, please visit our #ARCHIMED website 👇 https://lnkd.in/dxc2RfGV #ARCHIMED #ImpactingHealthcare #Lifescience #Cubebiotech #IBAlifesciences

Exciting News to share! The Cube Biotech Team is growing through the acquisition of IBA Lifesciences. Joining forces and technologies, the team will redefine protein purification for researchers worldwide. With Cube's NativeMP® platform and IBA's proven Strep-tag® technology, no protein target will be out of reach anymore.

Fem-Tech to become a $100bn market by 2030? According to Forbes, the term #FemTech was only founded in 2016 by Ada Tin. It was valued at $28bn in 2024 according to Dealroom.co and is set to more than triple by 2030! 📈 FemTech is focused on improving healthcare for women across #maternal, #menstrual, #pelvic and #sexual health along with general health conditions and we are seeing so much innovation and investment in this category. I have compiled a short snapshot of recent news within the sector along with Medexec's current mandates. #Congratulations to those mentioned in the post; Flo Health Inc. Europe's first unicorn, Founded by Dmitry Gurski who is the #CEO received $200M investment by General Atlantic.🦄 Hologic, Inc. well known for their aggressive M&A activity completed the acquisition of Gynesonics, Inc. who was led by Skip Baldino as #CEO Just yesterday, Gesynta Pharma AB Raised $29M Series B funding led by Innovestor focusing on the treatment of #endometriosis. Thank you for watching and reading and please reach out to the #medexec team for the latest executive hires and news or if you are a growing femtech business looking for your next hire.. #hiringfemtechsleadingexecs

Bird & Bird is proud to have successfully advised Nexstim Plc, a Finnish, globally operating medical technology company, on its cooperation and investment agreements with Brainlab AG, a leading German developer of advanced medical technology solutions.   The cooperation agreement aims at the advancement of non-invasive brain mapping technologies, as well as the distribution of certain Nexstim products by Brainlab. As part of this partnership, Brainlab and Nexstim have also agreed on a maximum of EUR 5,095,000 equity investment into Nexstim.   Our core advisory team included Maria Carlsson, Laura Huomo, Iina-Mari Supperi, Vuokko Rajamäki, Dr. Juliana Kliesch, Marla Melin, and Rondy Stenman.    Congratulations to all parties involved! 👏 We look forward to the advancements ahead. #twobirdsnordics #medtech #investments

50 Femovate Wins: Day #22 Afynia Laboratories closed a $2-million CAD round of pre-seed funding to develop and begin bringing EndomiR to market. EndomiR is a patented, research-backed, microRNA-based molecular screening test for endometriosis, a condition affecting 1 in 10 women worldwide. Congratulations Warren (Lauren) Foster, Ph.D., FCAHS and Jocelyn Wessels, Ph.D. We're excited to see what's next! About the 50 Femovate Wins: We're sharing 50 days of wins from all of the amazing startups in Femovate by Guidea. The wins might be investments, awards, milestone moments or reviews from real women saying how much these products and services have impacted their lives. Because that's why Femovate exists, to improve women's health equity around the globe. #femtech #healthinnovation #womenshealth #femovate50wins

Key insights from the Investival BioTech-HealthTech-MedTech event in London last week: - Major industry players are seeking highly differentiated technologies for acquisition. - Ageing patent portfolios are a significant concern for these players. - Speed and efficiency are pivotal in the early stages of development. - The majority of M&A deals are valued at over $250 million. - There is a trend towards indications with larger patient populations. - Areas like cardiovascular health and precision oncology stand out as critical areas with unmet needs. - Investor syndicates are encouraged to foster synergies for mutual benefit. - Notably, big players are showing interest in early-stage deals, not just in later stages. - Early-stage companies are advised to tap into the talent pool transitioning from larger corporations. - Highlighting compelling performance data is essential for enhancing visibility and attracting interest. - It is recommended that platform technologies be strategically segmented to optimize overall exit value. Overall, these trends are highly encouraging for ambitious young MedTech companies such as 4D Medicine Ltd and they reaffirm several key aspects of our investment proposition. #investival #medtechinvestment #SeriesA #SeriesB #Medtech

📢 𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗡𝗲𝘄𝘀 Cube Biotech is proud to announce the acquisition of IBA Lifesciences, forming a new authority dedicated to advancing life science research. By uniting our 𝗡𝗮𝘁𝗶𝘃𝗲𝗠𝗣™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 and purification resins with IBA’s 𝗦𝘁𝗿𝗲𝗽-𝘁𝗮𝗴® 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆, we’re unlocking unparalleled capabilities in protein stabilization and analysis. This synergy enables even the most challenging drug targets to be reached and streamlines the workflows of scientists around the world. The alliance reflects our commitment to accelerate innovation, simplify services, and expand our global presence. By combining our R&D resources, we’ll drive breakthroughs in membrane protein technologies—ensuring 𝘀𝘁𝗮𝗯𝗹𝗲 𝗽𝗿𝗼𝘁𝗲𝗶𝗻-𝗹𝗶𝗽𝗶𝗱 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝘀 for deeper insights. Together, we’re ushering in a new era of transformative discoveries across therapeutic development and beyond. At Cube Biotech, we remain focused on delivering customer-centric solutions. From #structuralinsights to high-throughput #screening, our integrated approach supports the next wave of scientific progress. We can’t wait to see what we’ll achieve together on this exciting journey! 🤝 #cubebiotech #ibalifesciences #lifesciencenews 

🚀 Exciting New Chapter for Cube Biotech and IBA Lifesciences! 🚀 As CEO of Cube Biotech, I’m thrilled to share the news of our transformative acquisition of IBA Lifesciences GmbH. This marks a significant step forward in our mission to push the boundaries of life science research and provide innovative solutions for protein purification, stabilization, and drug discovery. By uniting our expertise with IBA’s renowned technologies, we’re creating a powerhouse that delivers unparalleled solutions to researchers and industry professionals worldwide. Together, we will: ✅ Expand our global reach across North America, Europe, and Asia. ✅ Strengthen our product portfolio with Cube Biotech’s NativeMP® platform and IBA’s Strep-tag® technology. ✅ Drive innovation through combined R&D efforts. ✅ Offer tailored, customer-centric solutions for pharmaceutical, biotech, and academic partners. This is an exciting time for both teams, and our combined efforts will fuel innovation, collaboration, and, ultimately, groundbreaking discoveries in life sciences. I look forward to the journey ahead and welcome all collaborations, partnerships, and ideas to continue advancing this great field. #Innovation #Biotechnology #LifeSciences #Collaboration #GlobalGrowth #CubeBiotech #IBALifesciences #Leadership

🚀 Scailyte is kicking off its new fundraising campaign! 🚀 We’re building on our strong commercial traction from 2024 and the hot business pipeline developed by our CBO, Tim Foley, following deep-dive discussions with biotech and pharma leaders at JPM Week. Now, we are seeking like-minded investors who share our vision of a data-driven health future at single-cell resolution, where prevention and precision healthcare are driven by cutting-edge multi-omics data and AI. 🔬 Momentum: Precision medicine has entered the era of single-cell and multi-omics data, with big pharma companies already embracing this groundbreaking technology. The next frontier is bringing it to clinical routine, and Scailyte is leading the charge. 🏆 Pioneer: As an ETH Zürich spin-off, Scailyte has established a robust platform for biomarker and drug discovery, leveraging single-cell omics and proprietary AI algorithms. Over the past 7 years, we've developed multiple clinical biomarkers and built strategic partnerships with clinical-stage biotech and pharma companies. 🎯 Our Mission: Leverage single-cell multi-omics and AI to detect and treat diseases early & with high precision. 📢 Our CEO, Peter Nestorov, will be presenting Scailyte at: 📍 TechTour AI for Health – Bochum, Germany, Jan 23-24 📍 DeepTech Investor Summit – Zurich, Switzerland, Jan 27-28 Reach out to our CEO and join us in shaping the future of precision health. 🧬💙 #Scailyte #Fundraising #PrecisionMedicine #AIforHealth #SingleCellOmics #HealthcareInnovation #MultiOmics #ETHZurich #InvestingInTheFuture #Longevity #PrecisionHealth